Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 91

1.

Report of a phase 1/2 study of a combination of azacitidine and cytarabine in acute myelogenous leukemia and high-risk myelodysplastic syndromes.

Borthakur G, Huang X, Kantarjian H, Faderl S, Ravandi F, Ferrajoli A, Torma R, Morris G, Berry D, Issa JP.

Leuk Lymphoma. 2010 Jan;51(1):73-8. doi: 10.3109/10428190903318329.

2.

Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms.

Ye XN, Zhou XP, Wei JY, Xu GX, Li Y, Mao LP, Huang J, Ren YL, Mei C, Wang JH, Lou YJ, Ma LY, Yu WJ, Ye L, Xie LL, Luo YW, Hu C, Niu LM, Dou MH, Jin J, Tong HY.

Leuk Lymphoma. 2016;57(6):1311-8. doi: 10.3109/10428194.2015.1091931.

PMID:
26372888
3.
4.

Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia.

Song LX, Xu L, Li X, Chang CK, Zhang Y, Wu LY, He Q, Zhang QX, Li X.

Ann Hematol. 2012 Dec;91(12):1879-86. doi: 10.1007/s00277-012-1550-y.

PMID:
22895556
5.

Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS.

Mawad R, Becker PS, Hendrie P, Scott B, Wood BL, Dean C, Sandhu V, Deeg HJ, Walter R, Wang L, Myint H, Singer JW, Estey E, Pagel JM.

Br J Haematol. 2016 Jan;172(2):238-45. doi: 10.1111/bjh.13829.

PMID:
26568032
6.

Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia.

Issa JP, Garcia-Manero G, Huang X, Cortes J, Ravandi F, Jabbour E, Borthakur G, Brandt M, Pierce S, Kantarjian HM.

Cancer. 2015 Feb 15;121(4):556-61. doi: 10.1002/cncr.29085.

7.

Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes.

Prebet T, Braun T, Beyne-Rauzy O, Dreyfus F, Stammatoullas A, Wattel E, Ame S, Raffoux E, Delaunay J, Charbonnier A, Adès L, Fenaux P, Vey N.

Leuk Res. 2014 Jan;38(1):29-33. doi: 10.1016/j.leukres.2013.07.023.

PMID:
23953882
8.

The euphoria of hypomethylating agents in MDS and AML: is it justified?

Sekeres MA.

Best Pract Res Clin Haematol. 2013 Sep;26(3):275-8. doi: 10.1016/j.beha.2013.10.001. Review.

PMID:
24309530
9.

Decitabine in the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndromes, Which Combined with Complex Karyotype Respectively.

Gao S, Li Z, Fu JH, Hu XH, Xu Y, Jin ZM, Tang XW, Han Y, Chen SN, Sun AN, Wu DP, Qiu HY.

Asian Pac J Cancer Prev. 2015;16(15):6627-32.

10.
12.

Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias.

Giles FJ, Faderl S, Thomas DA, Cortes JE, Garcia-Manero G, Douer D, Levine AM, Koller CA, Jeha SS, O'Brien SM, Estey EH, Kantarjian HM.

J Clin Oncol. 2003 Mar 15;21(6):1050-6. Erratum in: J Clin Oncol. 2004 Apr 1;22(7):1351. Dosage error in published abstract; MEDLINE/PubMed abstract corrected; Dosage error in article text.

PMID:
12637470
13.
15.

A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome.

Kirschbaum M, Gojo I, Goldberg SL, Bredeson C, Kujawski LA, Yang A, Marks P, Frankel P, Sun X, Tosolini A, Eid JE, Lubiniecki GM, Issa JP.

Br J Haematol. 2014 Oct;167(2):185-93. doi: 10.1111/bjh.13016.

16.

Feasibility of azacitidine added to standard chemotherapy in older patients with acute myeloid leukemia--a randomised SAL pilot study.

Krug U, Koschmieder A, Schwammbach D, Gerss J, Tidow N, Steffen B, Bug G, Brandts CH, Schaich M, Röllig C, Thiede C, Noppeney R, Stelljes M, Büchner T, Koschmieder S, Dührsen U, Serve H, Ehninger G, Berdel WE, Müller-Tidow C.

PLoS One. 2012;7(12):e52695. doi: 10.1371/journal.pone.0052695.

17.
18.

The hypomethylating agent decitabine prior to chemotherapy improves the therapy efficacy in refractory/relapsed acute myeloid leukemia patients.

Jiang X, Wang Z, Ding B, Yin C, Zhong Q, Carter BZ, Yu G, Jiang L, Ye J, Dai M, Zhang Y, Liang S, Zhao Q, Liu Q, Meng F.

Oncotarget. 2015 Oct 20;6(32):33612-22. doi: 10.18632/oncotarget.5600.

19.

Phase I/II clinical study of topotecan and cytarabine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia and acute myeloid leukemia.

Weihrauch MR, Staib P, Seiberlich B, Hoffmann M, Diehl V, Tesch H.

Leuk Lymphoma. 2004 Apr;45(4):699-704.

PMID:
15160942
20.

Efficacy and feasibility of cyclophosphamide combined with intermediate- dose or high-dose cytarabine for relapsed and refractory acute myeloid leukemia (AML).

Schnetzke U, Fix P, Spies-Weisshart B, Schrenk K, Glaser A, Fricke HJ, La Rosée P, Hochhaus A, Scholl S.

J Cancer Res Clin Oncol. 2014 Aug;140(8):1391-7. doi: 10.1007/s00432-014-1666-7.

PMID:
24728467
Items per page

Supplemental Content

Support Center